Nabriva Therapeutics Submits Marketing Authorization App for Lefamulin to Treat Community-Acquired Pneumonia

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, announced that the Company’s  marketing authorization application (MAA) for both the intravenous (IV) and oral formulations of lefamulin, a potentially first-in-class, semi-synthetic pleuromutilin antibiotic, for the treatment of community-acquired pneumonia (CAP) in adults 18 years of age and older, has been submitted to...

Triclosan, a Common Antimicrobial Ingredient in Toothpaste, Soaps, Linked to Colonic Inflammation, Altered Gut Microbiota

A large research team led by senior author Guodong Zhang at the University of Massachusetts Amherst reports that the antimicrobial ingredient triclosan, found in hand soaps and toothpastes among other products, could have adverse effects on colonic inflammation and colon cancer by altering gut microbiota, the microbes found in our intestines. The study reported in Science...

Three-antibiotic cocktail clears ‘persister’ Lyme bacteria in mouse study

A new study from researchers at the Johns Hopkins Bloomberg School of Public Health found that a slow-growing variant form of Lyme bacteria caused severe symptoms in a mouse model. The slow-growing variant form of Lyme bacteria, according to the researchers, may account for the persistent symptoms seen in ten to twenty percent of Lyme patients that are not...

Phage viruses genetically engineered to kill bacteria rescue girl with antibiotic-resistant infection

One week after Helen Spencer's 15-year-old cystic fibrosis patient had a double lung transplant in September 2017, the incision wound turned bright red. For half her life, Isabelle Carnell had been battling a drug-resistant infection of Mycobacterium abscessus, and now it was rapidly spreading, erupting in weeping sores and swollen nodules across her frail body. "My heart sinks when I see that a...

Drug-resistant tuberculosis reversed in lab using new compound that prevents biofilm formation

Researchers at Washington University School of Medicine in St. Louis and Umea University in Sweden have found a compound that prevents and even reverses resistance to isoniazid, the most widely used antibiotic for treating tuberculosis, a disease that killed 1.5 million people in 2017. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. Once inside the body, the bacteria morph into a...

New Approach to Battling Antibiotic Resistant Bacteria Targets Bacterial DNA to Weaken Bacteria’s Defenses

Researchers at Jefferson University have been experimenting with ways to weaken the defenses of antibiotic resistant bacteria, by targeting a common feature of the resistant bacteria - a pair of membranes which are able to expel antibiotics by pumping them out of the cell. The researchers found a way to interfere with transfer RNA that is unique to the bacteria,...